Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

By sjmartinez • October 17, 2022

Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Oct 13:S1470-2045(22)00603-9. doi: 10.1016/S1470-2045(22)00603-9. Epub ahead of print. PMID: 36244398.

Tags: Digestive Diseases, Hematology/Oncology, Publications

Exploring Sex Differences in Irritable Bowel Syndrome Prevalence, Environmental Risk, and Comorbidities: A Population-Based Cohort Study of Veterans

Gasperi M, Gerstenberger A, Naliboff B, Afari N; VA Million Veteran Program. Exploring Sex Differences in Irritable Bowel Syndrome Prevalence, Environmental Risk, and Comorbidities: A[...]

Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies

Rozengurt E, Eibl G. Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies. Signal Transduct Target Ther. 2026 Jan 3;11(1):6. doi: 10.1038/s41392-025-02499-y. PMID: 41484057; PMCID: PMC12764932.

Increased Autoimmunity Burden Is a Risk Factor for Developing Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease

Chang A, Shahrvini B, Oh J, Prajapati DP, Baniqued M, Harmon R, Greb AC, Bonthala N, Sauk JS, Shin A, Chang L, Limketkai BN. Increased[...]